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ABSTRACT 
 
Benzothiazole is a heterocyclic compound formed by the fusion of benzene and thiazole ring. 
The moiety had been reported to act via competing with ATP binding site at the catalytic 
domain of tyrosine kinase. The present work involves the synthesis and biological evaluation 
of 4, 5 disubstituted imidazo [2, 1-b] benzothiazole derivatives. The antimicrobial activity of 
the synthesized derivatives was carried out against Gram + ve bacteria Staphylococcus aureus 
(MTCC 3160) and Gram –ve bacteria Bordetella bronchiseptica (MTCC 6838), 
Pseudomonas aeruginosa (T11) and fungal strains Candida albicans (MTCC 1637). 
Ciprofloxacin and Fluconazole were used as standard drug for antibacterial and antifungal 
activity respectively. The compounds 6a1, 6a2, 6a3, 6b1 and 8a1 exhibited good 
antimicrobial activity against all the strains.  The derivative 8a1 was further screened for 
anticancer activity against MCF-7 cell line using Doxorubicin as standard. The structures of 
the synthesized compounds were established by IR and NMR spectral studies. 
Introduction
Benzothiazole moiety is a versatile moiety that exhibits a wide 
variety of biological activities including antitubercular, 
antimalarial and anticonvulsant, antidiabetic, antimicrobial, 
antifungal and antitumor. Modifications on the benzothiazole 
have resulted in large number of compounds having diverse 
biological activities [1].  Benzothiazole act via competing with 
ATP for binding at catalytic domain of tyrosine kinase. The ATP 
binding site has the following features: Adenine region that 
contains two key hydrogen bonds formed by the interaction of 
N-1 and N-6 amino group of the adenine ring. Many potent 
inhibitors use one of these hydrogen bonds. The second is sugar 
region which is hydrophilic region, except a few e.g. EGFR. The 
third is hydrophobic pocket which is though not used by ATP 
but plays an important role in inhibitor selectivity. The fourth is 
hydrophobic channel which is not used by ATP and may be 
exploited for inhibitor specificity. The fifth is phosphate binding 
region which is used for improving inhibitor selectivity[2]. Now 
days, there is growing interest in the discovery of new 
antibacterial agents to bate against pathogenic microorganism, 
especially the bacteria resistant to the current antibiotics.   The 2-
substituted benzthiazole derivatives have been reported to 
possess very good antimicrobial properties[3]. The development 
of anticancer drug is more difficult than discovering cures for 
bacterial infection as there are very few biochemical differences 
between cancerous cell and normal cells. Moreover, the 
effectiveness of many drugs is limited by their toxicity to the 
normal rapidly growing cells in the intestinal and bone marrow 
areas. Also the cancerous cells which are initially suppressed by 
a specific drug may develop a resistance to that drug. Among the 
antitumor discovered in recent years, various benzothiazole 
derivatives possess potent anticancer properties e.g. 2-(4-amino-
3-methylphenyl)-5-fluorobenzothiazole (5F203) that acts 
through a novel mechanism. The 3-substituted-2-imino 
benzothiazolines were found to be three times more potent than 
Riluzole, a blocker of excitatory amino acids mediated 
neurotransmission [4-7]. 
In the past few years, molecularly targeted therapeutics has 
become an indispensable part of medicinal chemistry research. 
The hybridisation of two or more bioactive drug fragments with 
complementary functions or different mechanisms of action into 
a single molecule is a novel approach that often results in 
synergistic activity and enhanced drug efficacy. Solomon et al. 
was the first to report this dual action/hybrid pharmacophore 
strategy using isatin [8]. Following the same hybrid 
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pharmacophore strategy, the imidazobenzthiazole derivatives 
have been synthesized in the present work. 
Experimental 
The commercial chemicals employed for the present work were 
purchased from Sigma-Aldrich, Rankem and Loba Chem. All 
the solvents used were LR grade and were utilized in the 
reaction. The melting point was determined by open capillaries 
on Buchi-apparatus and is uncorrected. The reaction were 
monitored with the help of TLC using pre-coated aluminium 
sheets coated with 60F254 silica gel, 0.2 mm thickness from 
Merck. Various solvents systems used for developing 
chromatograms were (a) chloroform: methanol (9:0.5), (b) 
chloroform: ethyl acetoacetate (8.5:1.5), (c) Ethyl acetate: Pet. 
Ether (8:2) and U.V light chamber were used for the 
visualization of the TLC spots. The IR Spectra were recorded on 
an FT-IR Perkin-Elmer spectrophotometer (4000-400 cm-1). The 
1H NMR and 13C NMR spectra were recorded on Bruker Avance 
‖ 400 spectrometer where TMS was used as internal standard and 
chemical shifts are expressed as δ ppm. The Mass spectra were 
run on micromas Q-T of micro spectrometer at SAIF Punjab 
University, Chandigarh. 
Synthesis of Substituted 2-Amino Benzothiazole 
The appropriately substituted aniline (0.1mol) in 95% acetic acid 
(50 ml) was added to a solution of KSCN (0.2mol) in 95% acetic 
acid (100 ml). The mixture was cooled to 
0°C, and a solution of Br2 (0.1 mol) in acetic acid (30 ml) was 
added slowly with vigorous stirring so that the temperature 
remained between 0 and 10°C. After the addition was complete, 
the stirring was continued for 1h at 5°C and then the mixture was 
poured into water. The solid was collected and recrystallized 
from ethanol to yield substituted-2-thiocyanatoaniline. The 
product (0.036 mol), concentrated HCl (27 ml) and water (54 
ml) were refluxed for 2 h. The solution was cooled, and the 
product was filtered off, washed with water, and recrystallized 
from ethanol to yield the derivatives of 2-amino-4-(5-or 6-) 
substituted benzothiazole[9-10]. 
2-Amino benzothiazole (3a): Yield: 70%; State: Yellow 
powder; Melting point:                 226-228 ̊C; Rf  0.71 (Ethyl 
acetate: Pet. Ether 8:2). 
6-Methoxy-2-amino benzothiazole (3b): Yield: 64%; State: 
Grey powder; Melting point:                 228-232 ̊C; Rf  0.65 
(Ethyl acetate: Pet. Ether 8:2); IR (KBr, ν, cm-1): 1661 (C=N), 
609 (C-S-C), 3388 (NH2); 1H NMR (DMSO-d6, 400 MHz): δ 
3.72 (s, 3H, CH3), 6.75 (m, 1H, Ar), 7.23 (s, 2H, Ar). 
Synthesis of Substituted Imidazo-Benzthiazole Derivatives 
A mixture of equimolar quantities of substituted 2-amino 
benzothiazole (2.5 mmol) and substituted phenacyl bromide was 
heated to reflux on a water bath for 6-8 h, phosphorus pentoxide 
(0.75 mmol) was then added, and refluxing was continued for 
another 4-6 h. The reaction mixture was cooled overnight at 
room temperature. Excess of solvent was removed under reduced 
pressure and the crude product was filtered, washed with cold 
ethanol and dried. Neutralization of crude product with cold 
aqueous solution of Na2CO3 yielded the corresponding free 
bases, which were purified by recrystallization from dry ethanol. 
2-(4ʹ-Bromo) phenyl imidazo [2, 1-b] benzothiazole 5(a1): 
Yield: 60%; State: Yellow powder; Melting point: 290-294 C̊; Rf  
0.6 (Ethyl acetate: Pet. Ether 8:2); IR (KBr, ν, cm-1): 2977 (Ar-
H), 1691 (C=N), 748 (C-S-C); 1H NMR (DMSO-d6, 400 MHz): 
δ 8.69 (s, 1H, imidazole-H), 7.3 -7.9 (m, 8H, Ar-H). 
 2-(4ʹ-Fluoro) phenyl imidazo [2, 1-b] benzothiazole 5(a2): 
Yield: 64%; State: Yellow powder; Melting point: 290-295 C̊; Rf  
0.63 (Ethyl acetate: Pet. Ether 8:2).  1H NMR (DMSO-d6, 400 
MHz): δ 8.73 (s, 1H, imidazole-H), 8.0-8.3(m, 8H, Ar-H). 
2-(4ʹ-Methoxy) phenyl imidazo [2, 1-b] benzothiazole 5(a3): 
Yield: 55%; State: Light yellow powder; Melting point: 270-
273 C̊; Rf 0.54 (Ethyl acetate: Pet. Ether 8:2). 1H NMR (DMSO-
d6, 400 MHz): δ 8.71 (s, 1H, imidazole-H), 7.9-8.2 (m, 8H, Ar-
H). 
2-(4ʹ-Nitro) phenyl imidazo [2, 1-b] benzothiazole 5(a4): 
Yield: 70%; State: Red powder; Melting point: 283-287 C̊; Rf  
0.67 (Ethyl acetate: Pet. Ether 8:2); IR (KBr, ν, cm-1): 1685 
(C=N), 746 (C-S-C), 1517 (NO2), 2970 (Ar-H); 1H NMR 
(DMSO-d6, 400 MHz): δ 8.96 (s, 1H, imidazole-H), 7.4-8.4 (m, 
8H, Ar-H). 
6-Methoxy-2-(4ʹ-bromo) phenyl imidazo [2, 1-b] 
benzothiazole 5(b1): Yield: 53%; State: Light yellow powder; 
Melting point: 130-135 C̊; Rf  0.5 (Ethyl acetate: Pet. Ether 8:2); 
IR (KBr, ν, cm-1):1695 (C=N), 752 (C-S-C), 2972 (Ar-H), 1592 
(C-O); 1H NMR (DMSO-d6, 400 MHz): δ 8.84 (s, 1H, 
imidazole-H), 7.3-8.0 (m, 7H, Ar), 3.7- 3.9 (m, 3H, CH3). 
6-Methoxy-2-(4ʹ-fluoro) phenyl imidazo [2, 1-b] 
benzothiazole 5(b2): Yield: 57%; State: Pale yellow powder; 
Melting point: 140-145 ̊C; Rf  0.48 (Ethyl acetate: Pet. Ether 8:2). 
IR (KBr, ν, cm-1):1698 (C=N), 758 (C-S-C), 2989 (Ar-H), 1598 
(C-O);1H NMR (DMSO-d6, 400 MHz): δ 9.1 (s, 1H, imidazole-
H), 7.7-8.3 (m, 7H, Ar), 3.7- 4.3 (m, 3H, CH3). 
6-Methoxy-2-(4ʹ-methyl) phenyl imidazo [2, 1-b] 
benzothiazole 5(b3): Yield: 60%; State: Off white powder; 
Melting point: 137-140 ̊C; Rf  0.59 (Ethyl acetate: Pet. Ether 8:2). 
IR (KBr, ν, cm-1):1691 (C=N), 748 (C-S-C), 2964 (Ar-H), 1573 
(C-O);1H NMR (DMSO-d6, 400 MHz): δ 8.2 (s, 1H, imidazole-
H), 7.3-7.9 (m, 7H, Ar), 3.4-3.6 (m, 3H, CH3).  
6-Methoxy-2-(4ʹ-nitro) phenyl imidazo [2, 1-b] benzothiazole 
5(b4): Yield: 56%; State: Brown powder; Melting point: 155-
159 C̊; Rf  0.52 (Ethyl acetate: Pet. Ether 8:2). IR (KBr, ν, cm-
1):1700 (C=N), 767 (C-S-C), 3014 (Ar-H), 1612 (C-O);1H NMR 
(DMSO-d6, 400 MHz): δ 9.14 (s, 1H, imidazole-H), 7.7-8.3 (m, 
7H, Ar), 3.9-4.2 (m, 3H, CH3). 
Synthesis of 2, 3-Disubstituted Imidazo [2, 1-b] Benzthiazole 
Vilsmeir Haack reagent was prepared by adding phosphoryl-
chloride (3ml) in dimethyl formamide (20 ml) at 0 ̊C with 
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stirring. Then 5-(4-substituted)-phenyl imidazo-benzothiazole 
(0.16 mg ) 0.5 mmol was added to the reagent and stirred for 2 h 
at room temperature and at 60 ̊C for additional 2 h. The mixture 
was then poured in sodium carbonate solution and stirred at 90 ̊C 
for 2 h. after cooling the mixture was diluted with water and 
extracted with chloroform. The residue obtained was 
recrystallized from ethanol solvent to get crystalline solid. 
2-(4ʹ-Bromo) phenyl imidazo [2, 1-b] benzothiazole-3-
carbaldehyde 6(a1): Yield: 62%; State: Off white powder; 
Melting point: 100-105 ̊C; Rf  0.6 (Ethyl acetate: Pet. Ether 8:2); 
IR (KBr, ν, cm-1): 2970 (Ar-H), 1685 (C=O), 1602 (C=N), 746 
(C-S-C); 1H NMR (CDCl3,400 MHz): δ 7.9 (s, 1H, CHO), 7.2-
7.7 (m, 8H, Ar-H); 13C NMR (CDCl3): δ 148.26 (1C), 146.47 
(1C), 132.75 (1C), 131.98 (1C), 131.79 (1C), 130.22 (1C), 
126.64 (1C), 126.28 (1C), 125.04 (1C), 124.41 (1C), 121.22 
(1C), 112.67 (1C), 107.06 (1C), 77.41 (1C), 77.09 (1C), 76.77 
(1C); MS (ESI): m/z 329.158 (M+H)+ . 
2-(4ʹ-Fluoro) phenyl imidazo [2, 1-b] benzothiazole-3-
carbaldehyde 6(a2): Yield: 68%; State: Brown crystalline 
powder; Melting point: 220-224 ̊C; Rf  0.65 (Ethyl acetate: Pet. 
Ether 8:2); IR (KBr, ν, cm-1): 2885 (Ar-H), 1690 (C=O), 1619 
(C=N), 710 (C-S-C). 1H NMR (CDCl3,400 MHz): δ 8.2 (s, 1H, 
CHO), 7.9-8.2 (m, 8H, Ar-H); 
2-(4ʹ-Methoxy) phenyl imidazo [2, 1-b] benzothiazole-3-
carbaldehyde 6(a3): Yield: 50%; State: Brown crystal; Melting 
point: 135-140 C̊; Rf  0.49 (Ethyl acetate: Pet. Ether 8:2); IR 
(KBr, ν, cm-1): 2965 (Ar-H), 1705 (C=O), 1630 (C=N), 730 (C-
S-C). 1H NMR (CDCl3,400 MHz): δ 8.4 (s, 1H, CHO), 8.1-8.5 
(m, 8H, Ar-H). 
2-(4ʹ-Nitro) phenyl imidazo [2, 1-b] benzothiazole-3-
carbaldehyde 6(a4): Yield: 53%; State: Red colour powder; 
Melting point: 218-223 C̊; Rf  0.54 (Ethyl acetate: Pet. Ether 8:2); 
IR (KBr, ν, cm-1): 2972 (Ar-H), 1683 (C=O), 1597 (C=N), 751 
(C-S-C). 1H NMR (CDCl3,400 MHz): δ 9.1 (s, 1H, CHO), 8.4-
8.8 (m, 8H, Ar-H). 
6-Methoxy-2-(4ʹ-bromo) phenyl imidazo [2, 1-b] 
benzothiazole-3-carbaldehyde 6(b1): Yield: 53%; State: Red 
colour powder; Melting point: 220-224 C̊; Rf  0.5 (Ethyl acetate: 
Pet. Ether 8:2); IR (KBr, ν, cm-1): 2875 (Ar-H), 1715 (C=O), 
1607 (C=N), 1205 (C-O), 742 (C-S-C). 1H NMR (CDCl3,400 
MHz): δ 9.4(s, 1H, CHO), 8.3-8.8 (m, 8H, Ar-H); 3.5-3.7 (m, 
3H, CH3).  
6-Methoxy-2-(4ʹ-fluoro) phenyl imidazo [2, 1-b] 
benzothiazole-3-carbaldehyde 6(b2): Yield: 72%; State: 
Yellow powder; Melting point: 130-135 C̊; Rf  0.63 (Ethyl 
acetate: Pet. Ether 8:2); IR (KBr, ν, cm-1): 2895 (Ar-H), 1715 
(C=O), 1610 (C=N), 1262 (C-O), 715 (C-S-C). 1H NMR 
(CDCl3,400 MHz): δ 9.6 (s, 1H, CHO), 8.5-8.9 (m, 8H, Ar-H); 
3.6-3.9 (m, 3H, CH3).  
6-Methoxy-2-(4ʹ-methyl) phenyl imidazo [2, 1-b] 
benzothiazole-3-carbaldehyde 6(b3): Yield: 51%; State: Red 
powder; Melting point: 218-223 ̊C; Rf  0.59 (Ethyl acetate: Pet. 
Ether 8:2); IR (KBr, ν, cm-1): 2972 (Ar-H), 1720 (C=O), 1645 
(C=N), 1190 (C-O), 730 (C-S-C). 1H NMR (CDCl3,400 MHz): δ 
9.2 (s, 1H, CHO), 8.4-8.8 (m, 8H, Ar-H); 3.4-3.6 (m, 3H, CH3).  
6-Methoxy-2-(4ʹ-nitro) phenyl imidazo [2, 1-b] 
benzothiazole-3-carbaldehyde 6(b4): Yield: 63%; State: Red 
powder; Melting point: 130-135 ̊C; Rf  0.58 (Ethyl acetate: Pet. 
Ether 8:2); IR (KBr, ν, cm-1): 2878 (Ar-H), 1710 (C=O), 1623 
(C=N), 1195 (C-O), 720 (C-S-C). 1H NMR (CDCl3,400 MHz): δ 
9.7 (s, 1H, CHO), 8.8-9.1 (m, 8H, Ar-H); 3.7-3.9 (m, 3H, CH3).  
3-Nitroso-2-(4ʹ-Substituted) Phenyl Imidazo-Benzthiazole  
To a well stirred solution of 5-(4-substituted) phenyl-imidazo 
benzothiazole (0.16 mg 0.5 mmol) in acetic acid (10 ml) was 
added sodium nitrite solution (0.075 mg, in 5 ml water) dropwise 
at room temperature. After the addition, stirring was continued 
for 30 min and then mixture was refluxed for 2h. The mixture 
was poured in to ice cold water; separated crude solid was 
collected, washed with water, dried and recrystallized from 
ethanol.  
2-(4ʹ-Bromo) phenyl-3-nitroso imidazo [2, 1-b] benzothiazole 
7(a1): Yield: 60%; State: Red powder; Melting point: 160-
164 C̊; Rf  0.56 (Ethyl acetate: Pet. Ether 8:2); IR (KBr, ν, cm-1):  
2945 (Ar-H), 1630 (C=N), 1514 (N-O), 748 (C-S-C); 1H NMR 
(CDCl3, 400 MHz): δ 7.5-8.0 (m, 8H, Ar-H). 
2-(4ʹ-Fluoro) phenyl-3-nitroso imidazo [2, 1-b] benzothiazole 
7(a2): Yield: 62%; State: Pink powder; Melting point: 149-
154 C̊; Rf  0.6 (Ethyl acetate: Pet. Ether 8:2); IR (KBr, ν, cm-1):  
2972 (Ar-H), 1647 (C=N), 1498 (N-O), 725 (C-S-C). 1H NMR 
(CDCl3, 400 MHz): δ 7.7-8.2 (m, 8H, Ar-H). 
2-(4ʹ-Methoxy) phenyl-3-nitroso imidazo [2, 1-b] 
benzothiazole 7(a3): Yield: 60%; State: Red powder; Melting 
point: 140-144 C̊; Rf  0.52 (Ethyl acetate: Pet. Ether 8:2); IR 
(KBr, ν, cm-1): 2975 (Ar-H), 1649 (C=N), 1535 (N-O), 728 (C-S-
C). 1H NMR (CDCl3, 400 MHz): δ 7.8-8.3 (m, 8H, Ar-H). 
2-(4ʹ-Nitro) phenyl-3-nitroso imidazo [2, 1-b] benzothiazole 
7(a4): Yield: 55%; State: Light pink powder; Melting point: 
147-153 ̊C; Rf  0.6 (Ethyl acetate: Pet. Ether 8:2); IR (KBr, ν, cm-
1): 2985 (Ar-H), 1677 (C=N), 1498 (N-O), 755 (C-S-C). 1H 
NMR (CDCl3, 400 MHz): δ 7.9-8.4 (m, 8H, Ar-H). 
3-Bromo-2-(4-Bromo) Phenyl Imidazo-Benzothiazole 
To a well stirred solution of 2(4-substituted) imidazo [2, 1-b] 
benzothiazole (0.01 mol) in glacial acetic acid (5 ml) and 
anhydrous sodium acetate (0.02 mol), Bromine (0.1 ml) was 
added dropwise with stirring at room temperature. After the 
addition, stirring was continued for 2h. The reaction mixture was 
poured on to ice cold water and basified with ammonia solution. 
The separated solid was collected, washed with water and 
recrystallized with ethanol.  
3-Bromo-2-(4ʹ-bromo) phenyl imidazo [2, 1-b] benzothiazole 
8(a1): Yield: 64%; State: Yellow brown powder; Melting point: 
180-184 ̊C; Rf  0.71 (Ethyl acetate: Pet. Ether 8:2); IR (KBr, ν, 
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cm-1): 2972 (Ar-H), 1645 (C=N), 738 (C-S-C); 1H NMR (CDCl3, 
400 MHz): δ 7.6-8.1 (m, 8H, Ar-H). 
BIOLOGICAL SCREENING OF THE SYNTHESIZED 
COMPOUNDS 
Antimicrobial screening by agar diffusion method 
The antimicrobial screening of the synthesized compounds was 
carried out by cup plate agar diffusion method. All the 
synthesized compounds are evaluated to antibacterial and 
antifungal activity against Gram + ve bacteria Staphylococcus 
aureus (MTCC 3160) and Gram –ve bacteria Bordetella 
bronchiseptica (MTCC 6838), Pseudomonas aeruginosa (T11) 
and fungal strains Candida albicans (MTCC 1637) at IMTECH 
Chandigarh. The standards Ciprofloxacin and Fluconazole were 
dissolved in DMSO to get a concentration 100μg/ml for testing 
antibacterial and antifungal activity respectively. Each test 
compounds was dissolved in DMSO to get a concentration of 
100μg/ml for testing antibacterial activity. The zone of inhibition 
were observed and measured in mm. 
In vitro Anticancer screening 
In vitro anticancer screening was carried out using MTT assay 
method. For this firstly, the MTT solution (stock solution) was 
prepared by dissolving 5 mg MTT in 1 ml of PBS (Phosphate 
Buffer Saline). The cell line used for the study was MCF-7. 
TheMCF-7 cell line was maintained in 96 wells microliter plate 
containing MEM media supplemented with 10% heat inactivated 
fetal calf serum (FCS), containing 5% of mixture of Gentamicin 
(10ug), Penicillin (100 Units/ml) and Streptomycin (100μg/ml) 
in presence of 5% CO2 incubated at 37ºC for 48-72 hours. In-
vitro growth inhibition effect of test compound was assessed by 
calorimetric or spectrophotometric determination of conversion 
of MTT into “Formazan blue” by living cells. The final test 
concentrations of 10, 20, 25, 30 and 50μg/ml were added to the 
media. After 48 hrs incubation at 37ºC in a humidified 
atmosphere of 5% CO2, stock solution of MTT was added into 
each well (20μl, 5mg per ml in sterile (PBS) for further 4 hrs 
incubation. The supernatant carefully aspirated, the precipitated 
crystals of “Formazan blue’ were solubilized by adding DMSO 
(100μl) and optical density was measured at wavelength of 570 
nm by using ELISA plus. The results represent the mean of five 
readings. The concentration in which the OD of treated cells was 
reduced by 50% with respect to the untreated control, it is known 
as IC50 value. The % of Surviving cells which calculated by the 
formula that given below. 
 
Surviving cells (%) = Mean OD of test compound   x 100 
                                       Mean OD at control 
The % of Inhibition cells which calculated by the formula that 
given below 
Inhibition cells (%) = 100 - Surviving cells (%) 
IC50 value was calculated by using graph pad software. A graph 
presenting concentration (x-axis) vs % inhibition (y-axis) can be 
plotted to calculate the IC50 value. 
Results and Discussion 
The synthesis of 2,3-disubstituted imidazo [2, 1-b] benzthiazole 
was carried out as per the proposed protocol (Figure 1). The 2-
amino benzothiazole was synthesized in good yields by reacting 
substituted aniline with potassium thiocyanate and bromine. The 
reaction proceed via the intermediate substituted-2-
thiocyanatoaniline which refluxed for 2h in presence of HCl/H2O 
and form 2-substituted imidazo [2, 1-b] benzothiazole. Then 
prepared imidazo [2, 1-b] benzothiazole was treated with 
Vilsmeier hack reagent, nitration, bromination reaction to form 
3-substituted carbaldehyde, nitroso and bromine derivatives 
respectively. All the reactions were monitored through TLC 
observation till the completion using suitable mobile phase each 
time. After completion of the reaction, the products were 
purified by using suitable solvents e.g ethanol. The outcome of 
the present work has been summarized in Table 1. 
The purity of the compound was confirmed by TLC using 
precoated silica gel as a stationary phase, using appropriate 
solvent system as mobile phase and visualized under UV-light as 
well as analyzed. Structures of the title compounds were 
confirmed by FT-IR and 1H NMR spectral studies. The Rf  for 
the title compounds was observed between 0.49-0.71 using 
different solvent system and detecting agent. The Rf   for 
different imidazo-benzothiazole was found to be higher than the 
synthesized compounds. The melting point of all the compounds 
are in range between 115–295 C̊ and uncorrected. The melting 
point for all the precursors was found to be in agreement with 
the literature. The yield of all the synthesized derivatives was 
found in between 45-72%. The formation of 2–
Aminobenzothiazole by the reaction between aniline and 
potassium thiocyanate and bromine was confirmed by its IR 
spectrum. The formation of 2-aminobenzothiazole (3a, 3b) was 
confirmed by its IR spectrum that indicated the presence of C-N, 
N-H stretch complied with the spectra reported in the literature. 
Further the 1HNMR spectra displayed aromatic proton at δ 6.73 
and NH2 proton at δ 7.21. The structure of different 2-substituted 
imidazo [2, 1-b] benzothiazole derivatives were established by 
the absence of N-H stretch in the IR spectra between 1650-1580 
cm-1 region and appearance of singlet of imidazole proton (C5-H)  
around δ 8.69 in the 1H NMR confirms the formation of final 
ring system. The 2, 3-disubstituted imidazo [2, 1-b] 
benzothiazole derivatives clearly indicated the absence of 
imidazole proton (C5-H) around δ 8.0-9.0 in the 1H NMR. 
Antimicrobial activity 
The synthesized derivatives 6a1, 6a2, 6a3, 6b1, 7a3 and 8a1 
exhibited antimicrobial potential against Staphylococcus aureus 
(MTCC 3160), Pseudomonas aeruginosa (T11) and Candida 
albicans (MTCC 1637) during the primary screening of the 
compounds (Table 3). The active compounds were further 
screened at a concentration of 100µg/ml for test and standard 
against the same strains. The compound 2-(4-bromo) phenyl 
imidazo [2, 1-b] benzothiazole-3-carbaldehyde (6a1) and 3-
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bomo-2-(4-bromo) phenyl imidazo [2, 1-b] benzothiazole (8a1) 
had marked antimicrobial activity against all the strains. The 
compound 2-(4-fluoro) phenyl imidazo [2, 1-b] benzothiazole-3-
carbaldehyde (6a2), 2-(4-methoxy) phenyl imidazo [2, 1-b] 
benzothiazole-3-carbaldehyde(6a3), 6-methoxy-2-(4’-bromo) 
phenyl imidazo [2, 1-b] benzothiazole-3-carbaldehyde (6b1) had 
exhibited moderate activity. The detail with regard to zone of 
inhibition (in mm) has been summarized in Table 4. 
Anticancer screening using MTT Assay 
Biological (anticancer) activities of 2,3-disubstituted imidazo 
benzothiazole derivative was carried out on MCF-7 cancer cell-
line at IMTECH Chandigarh. Synthesized compounds 8a1 was 
screened for anticancer activity on MCF-7 cancer cell-line 
(Table 4 and figures 2-4). 
The synthesized compound possess better antimicrobial activity 
in comparison to the 2-substituted imidazo [2, 1-b] benzothiazole 
derivatives. Their better activity can be attributed to the presence 
of various electron withdrawing group substituted at position 3 
in the ring system. However, the synthesized derivatives can be 
further explored for better antimicrobial activity by studying 
their structure activity relationship. The compound 8a have 
exhibited encouraging activity on MCF-7 cell lines using 
Doxorubicin as standard indicating its potential as anticancer 
agent. 
 Conclusion 
 In the present study a total of 12 imidazo [2, 1-b] benzothiazole 
derivatives were synthesized. The compounds 6a1 and 8a1 
exhibited good antimicrobial activity as compared with standard 
drugs. The compound 8a1 have exhibited marked activity in both 
the antimicrobial as well as anticancer assays. The synthesized 
derivatives can be further explored for better antimicrobial 
activity by studying their structure activity relationship. The 
compound 8a can be utilized further to develop potential 
antimicrobial and anticancer agents. 
Table 1: Physical characteristic of synthesized compounds 
Sr. No Compounds Molecular Formula Molecular weight Melting point( ̊C) Yield(% ) Rf* 
1.  6a1 C16H9FN2OS 296.2 100 – 105 62 0.6 
2.  6a2 C16H9BrN2OS 358.2 220 – 224 68 0.65 
3.  6a3 C17H12N2O2S 308.3 135 – 140 50 0.49 
4.  6a4 C16H9N3O3S 323.3 218 - 223 53 0.54 
5.  6b1 C17H11FN2O2S 326.3 130 - 135 72 0.63 
6.  6b2 C17H11BrN2O2S 387.2 220 - 224 53 0.5 
7.  6b3 C18H14N2O2S 322.3 218 - 223 51 0.59 
8.  6b4 C17H11N3O4S 353.3 130 - 135 63 0.58 
9.  7a1 C15H8FN3O2S 313.2 160 - 164 60 0.56 
10.  7a2 C15H8BrN3O2S 374.2 149 - 154 62 0.6 
11.  7a3 C16H11N3O4S 325.3 140 - 144 60 0.5 
12.  7a4 C15H8BrN3O2S 340.2 147 - 153 55 0.6 
13.  8a1 C15H8Br2N2S 408.8 180 - 184 64 0.7 
*Ethyl acetate: Pet. Ether (8:2) 
Table 2: In vitro antimicrobial activity of synthesized compounds 
Compounds Bacterial Strains  Fungal Strain 
1&2 mg/mL Staphylococcus aureus  
(MTCC 3160) 
Pseudomonas 
aeruginosa 
(T11) 
Bordetella 
bronchiseptica 
(MTCC 6838) 
Candida albicans (MTCC 1637) 
6 a1 + + + + 
6 a2 + + + + 
6 a3 + + + + 
6 b1 + + + + 
6 b2 - - - - 
6 b3 - - - - 
7 a1 - - - - 
7a2 - - - - 
7 a3 + + + + 
8 a1 + + + + 
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Table 3:  In vitro antimicrobial activity against standard drug 
Compounds Zone of Inhibition (mm) 
Concentration Bacterial Strains Fungal Strain 
100 µg/mL Staphylococcus 
aureus  
(MTCC 3160) 
Pseudomonas 
aeruginosa 
(T11) 
Bordetella 
bronchiseptica 
(MTCC 6838) 
Candida albicans  
(MTCC 1637) 
6a1 21±1 20±1 18±3 18±2 
6a2 20±2 19±1 17±2 19±1 
6a3 19±1 18±2 15±2 17±2 
6b1 21±1 18±1 17±1 13±2 
7a3 20±2 17±2 14±1 15±1 
8a1 22±3 21±2 19±1 19±2 
St. 23±1* 28±2* 24±2* 22±2* 
St., Standard (Ciprofloxacin and Fluconazole); *± SD (n=3) mean of zone of inhibition in mm; NA, No activity.  
Table 4: In vitro anticancer activity of compound 8a in comparison to doxorubicin 
Sr. No. Compound CONCENTRATION(µg/ml) ABSORBANCE(nm) OBSERVATION IC50 (µg) 
1 Standard 
(Doxorubicin) 
2.5 0.610 No lysis  
 
10  
2 5 0.452 No lysis 
3 7.5 0.438 25% lysis 
4 10 0.358 50% lysis 
5 Control 0.668 No lysis 
1      8a1 10 0.446 50% lysis  
 
  10      
   
2 20 0.420 50% lysis 
3 25 0.416 >50% lysis 
4 30 0.415 >50% lysis 
5 50 0.413 >50% lysis 
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Figure 1:Scheme for the synthesis of 2,3-disubstituted imidazo [2, 1-b] benzthiazole derivatives 
Reagents and conditions (a) KSCN, Br2, H2O, stirring (b) HCl, H2O, reflux 2h (c) C2H5OH, P2O5, Na2CO3, 
reflux (d) DMF/POCl3, Na2CO3, stirring (e) NaNO2, AcOH, reflux 2h (f) Br2/AcOH, sodium acetate, stirring 
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Figure 2: Variation of  cell inhibition (%) vs dose ( g/ml) for Doxorubicin 
 
 
 
Figure 3:Variation of  cell inhibition (%) vs dose ( g/ml) for Compound 8a1 
 
 
 
 
 
 
   
10 μg/ml 20 μg/ml 25 μg/ml 30 μg/ml 50 μg/ml 
Figure 4: Photographs showing cell Lysis with different concentration of Compound 8a1 
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